Literature DB >> 18822830

Substance use disorders in adolescents with attention-deficit/hyperactivity disorder.

Oscar Bukstein1.   

Abstract

Attention-deficit/hyperactivity disorder and substance use disorders are commonly observed together, particularly in clinical populations of adolescents. The co-occurrence of these problems is common and presents challenges for the clinician in assessment and management. This article will review the extent of the problem, the relationship in terms of risk and prognosis, and management issues, including the use of stimulant and nonstimulant medications and the risk of abuse, misuse, and diversion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18822830

Source DB:  PubMed          Journal:  Adolesc Med State Art Rev        ISSN: 1934-4287


  5 in total

1.  Attention deficit hyperactivity symptoms and risky sexual behavior in young adult women.

Authors:  G M Monawar Hosain; Abbey B Berenson; Howard Tennen; Lance O Bauer; Z Helen Wu
Journal:  J Womens Health (Larchmt)       Date:  2012-02-03       Impact factor: 2.681

2.  Attention-deficit/hyperactivity disorder subtypes in adolescents with comorbid substance-use disorder.

Authors:  Leanne Tamm; Bryon Adinoff; Paul A Nakonezny; Theresa Winhusen; Paula Riggs
Journal:  Am J Drug Alcohol Abuse       Date:  2011-08-11       Impact factor: 3.829

3.  Pharmacotherapy for Substance Use Disorders in Youths.

Authors:  Christopher J Hammond; Kevin M Gray
Journal:  J Child Adolesc Subst Abuse       Date:  2016-04-20

4.  The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study.

Authors:  Zheng Chang; Paul Lichtenstein; Henrik Larsson
Journal:  J Abnorm Child Psychol       Date:  2012-04

5.  Maternal pre-pregnancy body mass index and offspring attention deficit hyperactivity disorder: a population-based cohort study using a sibling-comparison design.

Authors:  Qi Chen; Arvid Sjölander; Niklas Långström; Alina Rodriguez; Eva Serlachius; Brian M D'Onofrio; Paul Lichtenstein; Henrik Larsson
Journal:  Int J Epidemiol       Date:  2013-09-20       Impact factor: 7.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.